Pharmacokinetic and tissue penetration studies of grepafloxacin, a new broad-spectrum fluoroquinolone, show that it has useful properties for the treatment of respiratory tract infections. Grepafloxacin has a volume of distribution that is larger than those of many of the other fluoroquinolones and is concentrated in alveolar macrophages, bronchial mucosa and epithelial lining fluid to a greater extent than are certain other fluoroquinolones. Grepafloxacin concentrations achieved in plasma after a 400-mg oral dose are well in excess of those required to inhibit the respiratory pathogens Staphylococcus aureus, Haemophilus influenzae and Moraxella catarrhalis. Streptococcus pneumoniae is also covered for most of the dosing interval, but at normal dose levels grepafloxacin might not inhibit fnterococcus faecalis. The maximum plasma concentrations and area under the concentration-time curve achieved with grepafloxacin suggest that it will be effective for the treatment of community-acquired pneumonia and acute exacerbations of chronic bronchitis. The pharmacokinetics of fluoroquinolones are among their most useful properties. The aim of this paper is to demonstrate whether the differences between grepafloxacin and the other fluoroquinolones are of therapeutic significance.
STRUCTURE-ACTIVITY RELATIONSHIP
One of the main structural differences between grepafloxacin and other fluoroquinolones is the presence of the two amine groupings, a secondary and a tertiary amine, at position 7. Although difficult to prove, it is possible that the degree of amination of the molecule at this site may be related to some important pharmacokinetic properties. Although all fluoroquinolones have large volumes of distribution, fluoroquinolones with the structure described above tend to have larger volumes of distribution than the others [l] .
A volume of distribution of 1 L/kg is equivalent to the body volume being penetrated by the drug. A drug with a volume of distribution of 2 L/kg or more is being concentrated somewhere in the body. In general, the fluoroquinolones concentrate at two important sites: within the phagocytic cells of the body-the white blood cells and macrophages-and in the various mucosae of the body, often the site of infection.
Thus, high volumes of distribution, leading to high tissue levels of drug, particularly in the phagocytes and mucosa, are important pharmacokinetic characteristics of the fluoroquinolones.
PHARMACOKINETICS
In an early study using grepafloxacin, six healthy male volunteers (mean age 28 years, mean weight 73 kg) were given a single oral dose of grepafloxacin, 400 mg [2] . The levels of the drug were measured in plasma, in urine and in a cantharidin-induced inflammatory fluid model. The data were analyzed by a two-compartment (plasma) or one-compartment (inflammatory fluid) model.
There is considerable biological variation in the inflammatory fluid data using this model. After oral administration, grepafloxacin was shown to penetrate rapidly into plasma and, somewhat later though still fairly rapidly, into the inflammatory fluid (Figure 1 ). Peak concentration was achieved at about 2 h in plasma and at about 5 h in inflammatory fluid (Table 1) . After 5-6 h, the level of drug in the inflammatory fluid was higher than that in the plasma. The terminal half-life of grepafloxacin is approximately 12 h, and, even 12 h after a single dose, plasma levels are in excess of0.5 mg/L. Plasma levels at 24 h have been shown to be significant [3] .
Grepafloxacin's volume of distribution was 253 L, which conipares with 150 L for ciprofloxacin [4] . The percentage penetration of grepafloxacin into the inflammatory fluid was 180%, and this compares with 110% for ciprofloxacin [4] , 120% for sparfloxacin [S] and about 80% for ofloxacin [6] . Grepafloxacin penetrates into the inflammatory fluid to a greater extent than any other fluoroquinolone we have studied.
Other multidose pharmacokinetic studies have shown similar results, with grepafloxacin half-lives of about 12-1 5 h (Table 2) [3]. Doubling the dose doubles the area under the concentration-time curve (AUC).
Minimum inhibitory concentrations
An oral dose of grepafloxacin, 400 mg, achieves plasma concentrations that are well in excess of those required to inhibit (in an in vitro model) the respiratory pathogens Staphylococcus aureus, Haemoplzilus influenzae and Moraxella ratarrhalis [2, 7] . Streptocorcus pneumoniae was also covered for most of the dosing interval, but at normal dose levels grepafloxacin may not inhibit Enterococcus faecalis infections. H . injuenzae and M . catarrhalis were covered for some 36 h after a single oral dose of grepafloxacin, 400 mg [2, 7] .
Esckerichia coli and Salmonella spp. are extremely sensitive, and grepafloxacin would be expected to be active against them [8] . Grepafloxacin should not be used to treat infections with Pseudomonas aevuginosa or anaerobic organisms, such as Bacteroides spp.
Metabolism
In common with other fluoroquinolones, there is some nietabolisni of grepafloxacin with opening up of the ring structure at position 5, and some glucuronidation, the product of which has minimal microbiological activity compared to the parent compound. Grepafloxacin is eliminated by metabolism primarily through the liver. Metabolites account for less concentrated 2-3-fold [13] . In alveolar macrophages, than 10% of the dose in plasma, urine and feces.
W i s e : G r e p a f l o x a c i n : p h a r r n a c o k i n e t i c s a n d t i s s u e p e n e t r a t i o n
grepafloxacin is concentrated over 100-fold [ll], Urinary excretion of unchanged drug ranges from 6% compared with about 50-fold for ciprofloxacin [4] . to 14% [9] . A total of 27% of drug is eliminated
In comparison, if other classes of antimicrobial unchanged in the feces (data on file).
agents are considered, p-lactam concentrations in
TISSUE PENETRATION
Respiratory tract penetration by fluoroquinolones can be assessed by measuring antibiotic concentration in the sputum by endotracheal suction, bronchial biopsy or bronchoalveolar lavage. Grepafloxacin is found to accumulate in the polymorphonuclear cells (Figure 2) , where many pathogens can reside, and the concentrations achieved are greater than those for ofloxacin, levofloxacin and DR-3354 [lo] . In epithelial lining fluid, there are very high concentrations that peak in excess of 10 mg/L (Table 3, Figure 3 ) [11, 12] . Here, grepafloxacin is concentrated about 13-fold compared with ciprofloxacin, which concentrates 5-7-fold [4] . In bronchial mucosa, the mean levels exceed those in plasma by about three-fold [ 111. Other fluoroquinolones tend to be bronchial mucosa only achieve a b o u t 40% of s e r u m levels ( 
CORRELATION OF PHARMACODYNAMICS AND OUTCOME
The ratio of peak concentration t o MIC a n d of AUC to MIC are considered important for prediction of efficacy; w h i c h is used depends t o s o m e extent on t h e disease being treated. T h e Schentag data suggest that in nosocomial p n e u m o n i a t h e AUC/MIC ratio needed is about 1 2 5 : l [15] . T h i s is achieved for grepafloxacin. In community-acquired p n e u m o n i a , i n w h i c h it is n o t necessary t o be quite so rigorous as in nosocomial pneumonia, either an AUC/MIC ratio of 5O:l o r a p e a k / M I C ratio of 10 is considered reasonable [16] . Grepafloxacin would be expected t o be effective i n these two diseases, given that doses of 400 or 600 mg/day are used; w i t h a peak AUC of 19.7 mg/L/h, a grepafloxacin peak s e r u m level of about 1 . 4 mg/L a n d given a n MIC of Streptococcus pneumoniae of about 0.12 mg/L, the AUC/MIC ratio is about 150 a n d the p e a k / M I C ratio is about 12.
CONCLUSIONS
T h e fluoroquinolones are interesting agents from a pharmacokinetic viewpoint. They penetrate rapidly i n t o the blood, pass rapidly into extracellular fluid a n d inflammatory exudates, penetrate phagocytic cells (macrophages, white blood cells) a n d t h e mucosa a n d are concentrated in these sites a n d stdl maintain good s e r u m levels relative t o M I C s . As might be expected, there is less penetration i n t o s o m e of t h e more specialized sites of t h e body, such as cerebrospinal fluid a n d t h e anterior eye. For the important sites of common infections, such as lower respiratory tract infections, however, t h e high concentrations achieved with grepafloxacin are of considerable clinical importance.
